Last reviewed · How we verify
NCT03980509
A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors
Completed
Phase 1
Last updated 30 January 2025
What this trial tests
Phase 1 trial testing Curcumin in Breast Cancer in 22 participants. Completed in 24 March 2023.
Timeline
29 January 2020
Primary endpoint
24 March 2022
24 March 2022
24 March 2023
Quick facts
| Lead sponsor | Medical University of South Carolina |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 29 January 2020 |
| Primary completion | 24 March 2022 |
| Estimated completion | 24 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Curcumin (CURCUMIN) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Medical University of South Carolina
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9 -
Curcumin and Cancer.
Giordano A, Tommonaro G. · · 2019 · cited 588× · PMID 31590362 · DOI 10.3390/nu11102376 -
Natural Products as Anticancer Agents: Current Status and Future Perspectives.
Naeem A, Hu P, Yang M, Zhang J, et al · · 2022 · cited 292× · PMID 36500466 · DOI 10.3390/molecules27238367 -
Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy.
Dehelean CA, Marcovici I, Soica C, Mioc M, et al · · 2021 · cited 244× · PMID 33669817 · DOI 10.3390/molecules26041109 -
The Role of Curcumin in Cancer Treatment.
Zoi V, Galani V, Lianos GD, Voulgaris S, et al · · 2021 · cited 156× · PMID 34572272 · DOI 10.3390/biomedicines9091086 -
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.
Antao AM, Tyagi A, Kim KS, Ramakrishna S. · · 2020 · cited 126× · PMID 32549302 · DOI 10.3390/cancers12061579 -
A Comprehensive Review on the Benefits and Problems of Curcumin with Respect to Human Health.
Liu S, Liu J, He L, Liu L, et al · · 2022 · cited 77× · PMID 35889273 · DOI 10.3390/molecules27144400 -
Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H, Zhang Y, Jia Y, Chen X, et al · · 2024 · cited 54× · PMID 38283176 · DOI 10.1002/mco2.470
Verify or expand the search:
- PubMed search for NCT03980509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Curcumin
Trials testing the same drug.
- NCT07436130 — Curcumin in Critically Ill Patients With Sepsis · NA · not yet recruiting
- NCT07251985 — Cognitive Effects of Bioavailable Curcumin · Phase 2 · not yet recruiting
- NCT07379177 — Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human · NA · not yet recruiting
- NCT07523256 — Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia · NA · completed
- NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance · EARLY_PHASE1 · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
- NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
- NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
- NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03980509 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing